Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gefitinib induces myeloid differentiation of acute myeloid leukemia.
Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Stegmaier K, et al. Among authors: deangelo dj. Blood. 2005 Oct 15;106(8):2841-8. doi: 10.1182/blood-2005-02-0488. Epub 2005 Jul 5. Blood. 2005. PMID: 15998836 Free PMC article.
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Wadleigh M, et al. Among authors: deangelo dj. Blood. 2003 Sep 1;102(5):1578-82. doi: 10.1182/blood-2003-01-0255. Epub 2003 May 8. Blood. 2003. PMID: 12738663 Free article.
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR. Jiang J, et al. Among authors: deangelo dj. Blood. 2004 Sep 15;104(6):1855-8. doi: 10.1182/blood-2004-02-0712. Epub 2004 Jun 3. Blood. 2004. PMID: 15178581 Free article.
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Stone RM, et al. Among authors: deangelo dj. Blood. 2005 Jan 1;105(1):54-60. doi: 10.1182/blood-2004-03-0891. Epub 2004 Sep 2. Blood. 2005. PMID: 15345597 Free article. Clinical Trial.
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. Pikman Y, et al. Among authors: deangelo dj. PLoS Med. 2006 Jul;3(7):e270. doi: 10.1371/journal.pmed.0030270. PLoS Med. 2006. PMID: 16834459 Free PMC article.
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. DeAngelo DJ, et al. Blood. 2006 Dec 1;108(12):3674-81. doi: 10.1182/blood-2006-02-005702. Epub 2006 Aug 10. Blood. 2006. PMID: 16902153 Free PMC article. Clinical Trial.
310 results